Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TG02 in Anaplastic Astrocytoma or Glioblastoma (STEAM)
NCT03224104Phase 1Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jun 2018
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of zotiraciclib in anaplastic astrocytoma (AA) and glioblastoma (GBM) (3 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoints: Maximum Tolerated Dose at 28 days and Progression-free Survival at 6 Months. Started Jun 2018; status: completed.
02
Drugs
zotiraciclib
03
Conditions
anaplastic astrocytoma (AA)glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03224104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03224104.